HSP90-METTL3 Axis Regulates MYC m6A Modification in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) is a leading cause of cancer mortality globally, with incidence projected to rise by up to 70% by 2035. Despite therapeutic advances, CRC remains challenging due to its complex genetic and epigenetic landscape. One emerging area of interest is RNA methylation, especially N6-methyladenosine (m⁶A) modification, which regulates RNA metabolism and oncogene expression. The methyltransferase METTL3, critical for m⁶A installation, is frequently dysregulated in cancers, yet the mechanisms controlling its stability and function in CRC are not fully understood. The reference study addresses whether the molecular chaperone heat shock protein 90 (HSP90) sustains METTL3 stability and how disrupting this axis could impact MYC-driven oncogenesis in CRC (Meng et al., 2026).

Key Innovation from the Reference Study

The principal innovation lies in delineating a direct chaperone-client relationship between HSP90 and METTL3, with important therapeutic implications. The authors show that METTL3 is a bona fide client of HSP90, stabilized through direct interaction with the HSP90 middle domain. Pharmacological inhibition of HSP90 using 17-AAG selectively destabilizes METTL3 by enhancing K48-linked polyubiquitination via the E3 ligase CHIP. This targeted degradation of METTL3 leads to reduced m⁶A modification of MYC mRNA, shortening its half-life and suppressing MYC-driven oncogenic programs in CRC cells. The study extends the paradigm of HSP90 clients beyond classical kinases and transcription factors to key RNA-modifying enzymes, revealing a novel regulatory axis for RNA epigenetics in cancer.

Methods and Experimental Design Insights

The authors employed a multi-level experimental approach, including:

• Analysis of HSP90AA1 and METTL3 expression in CRC patient tissues and cell lines, confirming their overexpression and positive correlation.
• Co-immunoprecipitation and domain-mapping experiments to determine the direct interaction between HSP90 and the MTA70 domain of METTL3.
• Treatment of CRC cell lines with the HSP90 inhibitor 17-AAG to assess effects on METTL3 protein stability, ubiquitination, and subcellular distribution.
• RNA-seq and m⁶A-seq to profile transcriptome-wide changes in gene expression and methylation after 17-AAG treatment.
• Functional assays including proliferation, colony formation, invasion, migration, and cancer stemness following manipulation of HSP90, METTL3, and MYC pathways.
• Rescue experiments with the METTL3-METTL14 agonist MPCH and MYC-stabilizing compound NNK to dissect pathway specificity.

These methods collectively strengthen the causal link between HSP90 chaperoning of METTL3, MYC mRNA stability, and CRC malignancy.

Core Findings and Why They Matter

The study demonstrates:

• HSP90 stabilizes METTL3: HSP90 binds directly to METTL3’s MTA70 domain, preventing its CHIP-mediated K48-linked polyubiquitination and proteasomal degradation in both nucleus and cytoplasm.
• HSP90 inhibition reduces METTL3 and MYC m⁶A methylation: 17-AAG treatment leads to rapid degradation of METTL3, selectively decreasing m⁶A levels on MYC mRNA and reducing its half-life and protein output, without affecting METTL3 transcription.
• Transcriptome-wide effects: RNA-seq identified 1,158 genes with altered expression and m⁶A methylation after HSP90 inhibition, underscoring the broad regulatory impact of this axis.
• Suppressed oncogenic phenotypes: HSP90 inhibition impairs CRC cell proliferation, stemness, invasion, and migration, effects that are partially reversed by METTL3-METTL14 agonist MPCH. Similarly, direct METTL3 inhibition (STM2457) mimics these effects, which can be partly rescued by stabilizing MYC protein (NNK).

These findings reveal that the HSP90-METTL3 axis is a critical regulator of MYC mRNA methylation and stability, and hence, CRC cell malignancy. Targeting this axis represents a promising strategy to disrupt oncogenic RNA regulation in CRC (Meng et al., 2026).

Protocol Parameters

• HSP90 inhibition: 17-AAG applied at concentrations determined by cell viability and optimal suppression of METTL3; typically 0.5–2 μM for 24–48 hours in CRC cell lines.
• Protein extraction: Use of a broad-spectrum protease inhibitor cocktail (e.g., targeting serine, cysteine, aspartic proteases, and aminopeptidases) during lysis to preserve protein integrity, as recommended for Western blot, Co-IP, and pull-down assays.
• Ubiquitination assays: Inclusion of proteasome inhibitors as appropriate to capture transiently polyubiquitinated METTL3.
• RNA stability assays: Transcriptional block (e.g., actinomycin D at 5 μg/mL) followed by time-course qPCR to determine MYC mRNA half-life.

Comparison with Existing Internal Articles

This work advances the understanding of oncogenic protein stability and RNA regulation, complementing insights from internal reviews on protein integrity in cancer research. For example, the article "Integrating Protease Inhibitor Cocktail K1019 for Advanced Protein Integrity in Cancer Research" details how robust protein degradation prevention is vital for accurate assessment of signaling pathways, especially when studying labile chaperone-client interactions (see internal analysis). Similarly, "Protease Inhibitor Cocktail: Elevating Protein Integrity in Oncology" underscores the necessity of comprehensive protease inhibition when performing Western blotting or co-immunoprecipitation in oncology workflows (internal discussion). The current reference study directly benefits from such technical rigor, as precise measurement of METTL3 stability and ubiquitination critically depends on minimizing artifactual protein loss during extraction and analysis.

Limitations and Transferability

Several limitations should be acknowledged. First, the study’s mechanistic insights are primarily derived from CRC models; applicability to other cancer types awaits validation. Second, while CHIP-mediated ubiquitination is shown to target METTL3 upon HSP90 inhibition, other E3 ligases may also contribute, and their roles remain to be explored. Third, although transcriptomic changes are documented, functional consequences for m⁶A-modified transcripts beyond MYC require further investigation. Finally, the in vivo relevance and therapeutic window of manipulating the HSP90-METTL3 axis in clinical CRC warrants deeper study. Nevertheless, the demonstration that RNA-modifying enzymes can be regulated at the protein stability level by chaperones significantly broadens the conceptual landscape of cancer epigenetics.

Research Support Resources

Reproducible protein extraction and analysis are essential for studies of proteasomal degradation and chaperone-client dynamics. Researchers can use the Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) (SKU K1019) to ensure comprehensive inhibition of serine, cysteine, and aspartic proteases, as well as aminopeptidases, during cell lysis and protein extraction. This serine protease inhibitor cocktail is suitable for workflows such as Western blotting and co-immunoprecipitation, helping to prevent artifactual protein degradation (see workflow evidence). For best results, follow recommended protocols regarding EDTA removal prior to metal-affinity chromatography applications. Such technical safeguards can support the robust analysis of protein stability and ubiquitination in future chaperone-client studies.